These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 9731088)
1. An assessment of heart-valve abnormalities in obese patients taking dexfenfluramine, sustained-release dexfenfluramine, or placebo. Sustained-Release Dexfenfluramine Study Group. Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT N Engl J Med; 1998 Sep; 339(11):725-32. PubMed ID: 9731088 [TBL] [Abstract][Full Text] [Related]
2. Echocardiographic prevalence of mitral and/or aortic regurgitation in patients exposed to either fenfluramine-phentermine combination or to dexfenfluramine. Kancherla MK; Salti HI; Mulderink TA; Parker M; Bonow RO; Mehlman DJ Am J Cardiol; 1999 Dec; 84(11):1335-8. PubMed ID: 10614800 [TBL] [Abstract][Full Text] [Related]
3. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. Khan MA; Herzog CA; St Peter JV; Hartley GG; Madlon-Kay R; Dick CD; Asinger RW; Vessey JT N Engl J Med; 1998 Sep; 339(11):713-8. PubMed ID: 9731086 [TBL] [Abstract][Full Text] [Related]
4. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. Jick H; Vasilakis C; Weinrauch LA; Meier CR; Jick SS; Derby LE N Engl J Med; 1998 Sep; 339(11):719-24. PubMed ID: 9731087 [TBL] [Abstract][Full Text] [Related]
5. Valvular abnormalities and cardiovascular status following exposure to dexfenfluramine or phentermine/fenfluramine. Gardin JM; Schumacher D; Constantine G; Davis KD; Leung C; Reid CL JAMA; 2000 Apr; 283(13):1703-9. PubMed ID: 10755496 [TBL] [Abstract][Full Text] [Related]
6. Prevalence of valvular-regurgitation associated with dexfenfluramine three to five months after discontinuation of treatment. Weissman NJ; Tighe JF; Gottdiener JS; Gwynne JT J Am Coll Cardiol; 1999 Dec; 34(7):2088-95. PubMed ID: 10588229 [TBL] [Abstract][Full Text] [Related]
7. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Ryan DH; Bray GA; Helmcke F; Sander G; Volaufova J; Greenway F; Subramaniam P; Glancy DL Obes Res; 1999 Jul; 7(4):313-22. PubMed ID: 10440587 [TBL] [Abstract][Full Text] [Related]
8. Clinical and echocardiographic follow-up of patients previously treated with dexfenfluramine or phentermine/fenfluramine. Gardin JM; Weissman NJ; Leung C; Panza JA; Fernicola D; Davis KD; Constantine GD; Reid CL JAMA; 2001 Oct 24-31; 286(16):2011-4. PubMed ID: 11667938 [TBL] [Abstract][Full Text] [Related]
9. The progression of fenfluramine-associated valvular heart disease assessed by echocardiography. Mast ST; Jollis JG; Ryan T; Anstrom KJ; Crary JL Ann Intern Med; 2001 Feb; 134(4):261-6. PubMed ID: 11182835 [TBL] [Abstract][Full Text] [Related]
10. Natural history of valvular regurgitation 1 year after discontinuation of dexfenfluramine therapy. A randomized, double-blind, placebo-controlled trial. Weissman NJ; Panza JA; Tighe JF; Gwynne JT Ann Intern Med; 2001 Feb; 134(4):267-73. PubMed ID: 11182836 [TBL] [Abstract][Full Text] [Related]
11. Fenfluramine and phentermine and cardiovascular findings: effect of treatment duration on prevalence of valve abnormalities. Jollis JG; Landolfo CK; Kisslo J; Constantine GD; Davis KD; Ryan T Circulation; 2000 May; 101(17):2071-7. PubMed ID: 10790349 [TBL] [Abstract][Full Text] [Related]
12. Effect of fenfluramine-derivative diet pills on cardiac valves: a meta-analysis of observational studies. Sachdev M; Miller WC; Ryan T; Jollis JG Am Heart J; 2002 Dec; 144(6):1065-73. PubMed ID: 12486432 [TBL] [Abstract][Full Text] [Related]
13. Appetite suppressants and valvular heart disease in a population-based sample: the HyperGEN study. Palmieri V; Arnett DK; Roman MJ; Liu JE; Bella JN; Oberman A; Kitzman DW; Hopkins PN; Morgan D; de Simone G; Devereux RB Am J Med; 2002 Jun; 112(9):710-5. PubMed ID: 12079711 [TBL] [Abstract][Full Text] [Related]
14. Low risk of significant echocardiographic valvulopathy in patients treated with anorectic drugs. Burger AJ; Charlamb MJ; Singh S; Notarianni M; Blackburn GL; Sherman HB Int J Cardiol; 2001 Jul; 79(2-3):159-65. PubMed ID: 11461737 [TBL] [Abstract][Full Text] [Related]
15. Echocardiographic improvement over time after cessation of use of fenfluramine and phentermine. Hensrud DD; Connolly HM; Grogan M; Miller FA; Bailey KR; Jensen MD Mayo Clin Proc; 1999 Dec; 74(12):1191-7. PubMed ID: 10593346 [TBL] [Abstract][Full Text] [Related]
16. Diet drug-related cardiac valve disease: the Mayo Clinic echocardiographic laboratory experience. Teramae CY; Connolly HM; Grogan M; Miller FA Mayo Clin Proc; 2000 May; 75(5):456-61. PubMed ID: 10807073 [TBL] [Abstract][Full Text] [Related]
18. Risk for valvular heart disease among users of fenfluramine and dexfenfluramine who underwent echocardiography before use of medication. Wee CC; Phillips RS; Aurigemma G; Erban S; Kriegel G; Riley M; Douglas PS Ann Intern Med; 1998 Dec; 129(11 Pt 1):870-4. PubMed ID: 9867728 [TBL] [Abstract][Full Text] [Related]
19. Heart valve lesions in patients treated with appetite suppressants. Pi-Sunyer FX Obes Res; 1999 Jul; 7(4):414-6. PubMed ID: 10440599 [No Abstract] [Full Text] [Related]
20. [Appetite suppressants and heart valve disorders]. Adams C; Cohen A Arch Mal Coeur Vaiss; 1999 Sep; 92(9):1213-9. PubMed ID: 10533670 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]